Piramal Pharma Achieves Successful Closure of US FDA Inspection at Kentucky Facility
Piramal Pharma Ltd has confirmed the successful completion of its US FDA inspection at its manufacturing facility located in Lexington, Kentucky, USA. The successful conclusion was marked by the receipt of the Establishment Inspection Report (EIR) from the US FDA.The company reported that the US FDA has issued the Establishment Inspection Report (EIR) for the Lexington facility. The report carries the classification of Voluntary Action Indicated (VAI).
The receipt of this EIR marks the successful closure of the inspection process for Piramal Pharma Ltd at the specified US location.
PPLPHARMA Stock Price Movement
Shares of Piramal Pharma Limited are edging higher to ₹146.41 as of 10:22 AM today, gaining 0.29% in live trading. The stock activity remains robust, marked by a total volume of 764,138 shares traded so far in the session.Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.